Catapano Lisa A, Manji Husseini K
Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, HHS, Bethesda, MD, USA.
Drug Discov Today. 2008 Apr;13(7-8):295-302. doi: 10.1016/j.drudis.2008.02.007. Epub 2008 Apr 3.
Bipolar disorder is one of the most severely debilitating of all medical illnesses, and is increasingly recognized as a major public health problem. For many patients with bipolar disorder, current pharmacotherapy is insufficient. Exciting recent data suggest that regulation of signaling molecules may be involved in the pathophysiology of the disorder, and in the mechanisms of action of mood stabilizers and antidepressants. Through our developing understanding of the biochemical targets of effective medications, several potential targets for new therapies have emerged. This short review will focus on two of the most promising such targets: glycogen synthase-3 and protein kinase C.
双相情感障碍是所有医学疾病中最严重的致残性疾病之一，并且越来越被视为一个重大的公共卫生问题。对于许多双相情感障碍患者来说，目前的药物治疗并不充分。最近令人兴奋的数据表明，信号分子的调节可能参与了该疾病的病理生理学过程，以及情绪稳定剂和抗抑郁药的作用机制。随着我们对有效药物生化靶点的不断深入了解，已经出现了几个新疗法的潜在靶点。这篇简短的综述将聚焦于两个最有前景的此类靶点：糖原合酶-3和蛋白激酶C。
